In gastric cancer, which is the fifth most common cancer and the third leading cause of cancer-related mortality, anti-programmed cell death protein 1 (PD-1) monoclonal antibodies have been approved in the chemorefractory setting for Asian patients and a subset of PD-L1-positive patients with advanced gastro-oesophageal adenocarcinoma. This evidence concerns the gene PDCD1 and cancer.